144 related articles for article (PubMed ID: 38145494)
21. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
22. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534
[TBL] [Abstract][Full Text] [Related]
23. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318
[No Abstract] [Full Text] [Related]
24. Importance of molecular features of non-small cell lung cancer for choice of treatment.
Moran C
Am J Pathol; 2011 May; 178(5):1940-8. PubMed ID: 21514411
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
Ohashi K; Maruvka YE; Michor F; Pao W
J Clin Oncol; 2013 Mar; 31(8):1070-80. PubMed ID: 23401451
[TBL] [Abstract][Full Text] [Related]
26. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Hishida T; Nagai K; Mitsudomi T; Yokoi K; Kondo H; Horinouchi H; Akiyama H; Nagayasu T; Tsuboi M;
J Thorac Cardiovasc Surg; 2010 Nov; 140(5):e69-71. PubMed ID: 20674944
[No Abstract] [Full Text] [Related]
27. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
Yang WJ; Gao YB; Qiu T; Wang YG; He J
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
[No Abstract] [Full Text] [Related]
28. Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol.
Kitagawa C; Kada A; Saito AM; Ichinose Y; Saka H
Kurume Med J; 2019 May; 65(2):77-81. PubMed ID: 30429415
[TBL] [Abstract][Full Text] [Related]
29. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
[No Abstract] [Full Text] [Related]
30. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
Ma F; Shi X; Meng W; Zhang J; Zhao L; He X; Zhao J
Zhongguo Fei Ai Za Zhi; 2014 Jul; 17(7):575-80. PubMed ID: 25034590
[TBL] [Abstract][Full Text] [Related]
31. [Advances of heterogeneity of EGFR in non-small cell lung cancer].
Zheng H; Zhang H; Shi H; Li B
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):890-3. PubMed ID: 22104226
[No Abstract] [Full Text] [Related]
32. Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.
Lim JU
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):619-626. PubMed ID: 34364740
[TBL] [Abstract][Full Text] [Related]
33. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Wu YL; Herbst RS; Mann H; Rukazenkov Y; Marotti M; Tsuboi M
Clin Lung Cancer; 2018 Jul; 19(4):e533-e536. PubMed ID: 29789220
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
35. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Azuma K; Nishio M; Hayashi H; Kiura K; Satouchi M; Sugawara S; Hida T; Iwamoto Y; Inoue A; Takeda K; Ikeda S; Nakagawa T; Takeda K; Asahina S; Komatsu K; Morita S; Fukuoka M; Nakagawa K
Cancer Sci; 2018 Aug; 109(8):2532-2538. PubMed ID: 29807396
[TBL] [Abstract][Full Text] [Related]
36. Third-generation EGFR-TKIs—a new hope for NSCLC.
Akkermans R
Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
[No Abstract] [Full Text] [Related]
37. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
[TBL] [Abstract][Full Text] [Related]
38. Akatsuki disease in a patient using an epidermal growth factor receptor-tyrosine kinase inhibitor.
Oda N; Nakagawa Y; Takata I
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35027383
[No Abstract] [Full Text] [Related]
39. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
40. Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond.
Rocco D; Battiloro C; Gravara LD; Gridelli C
Rev Recent Clin Trials; 2019; 14(2):120-128. PubMed ID: 30520383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
